We thank our donors for their generous support of this program, which has advanced medical innovation and made a lasting impact on the health of our community.”
It’ s worth noting that Renown Health is the first health system in northern Nevada, including all northern California, to adopt these groundbreaking technologies. This achievement is particularly significant considering patients formerly had to travel from northern Nevada to California in search of similar care.
Renown Regional Medical Center Using FDA-Approved Tnkase ® to Treat Ischemic Stroke
Renown Regional Medical Center, the only Joint Commission-certified Comprehensive Stroke Center in northern Nevada since 2019, is now using the newly FDA-approved TNKase ®( Tenecteplase) to treat eligible adults experiencing acute ischemic stroke- offering patients faster, more effective clot-dissolving treatment with improved outcomes.
The U. S. Food and Drug Administration recently approved TNKase ® for use in treating acute ischemic stroke in adults within 4.5 hours of symptom onset.
“ TNKase ® represents an important advancement in stroke care,” said Benjamin Tim Pence, DO, Medical Director of the Renown Institute for Neurosciences.“ Compared to the traditional clot-busting drug alteplase( tPA), TNKase ® is given as a single IV bolus rather than a one-hour infusion. This simplifies and accelerates treatment, allowing us to restore blood flow more quickly and potentially improving outcomes for our patients.”
Renown Health | Physician Pulse Newsletter | 11